Early research (Phase 1)Study completedNCT02961881
What this trial is testing
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
Who this might be right for
Non-Hodgkin's Lymphoma
Amgen 35